KR930002327A - 치환된 시클로프로필아미노-1, 3, 5-트리아진 - Google Patents

치환된 시클로프로필아미노-1, 3, 5-트리아진 Download PDF

Info

Publication number
KR930002327A
KR930002327A KR1019920013231A KR920013231A KR930002327A KR 930002327 A KR930002327 A KR 930002327A KR 1019920013231 A KR1019920013231 A KR 1019920013231A KR 920013231 A KR920013231 A KR 920013231A KR 930002327 A KR930002327 A KR 930002327A
Authority
KR
South Korea
Prior art keywords
cyclopropylamino
triazine
thiomorpholino
formula
substituted
Prior art date
Application number
KR1019920013231A
Other languages
English (en)
Other versions
KR100221400B1 (ko
Inventor
얀 반 코일렌 베렌트
골드슈타인 솔로
코쎄멘트 에릭
고베르트 쟝
뷜페르트 에른스트
Original Assignee
알. 뒤셀도르프, 아이.시.아이.에이.
유시비 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알. 뒤셀도르프, 아이.시.아이.에이., 유시비 에스.에이. filed Critical 알. 뒤셀도르프, 아이.시.아이.에이.
Publication of KR930002327A publication Critical patent/KR930002327A/ko
Application granted granted Critical
Publication of KR100221400B1 publication Critical patent/KR100221400B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epoxy Resins (AREA)

Abstract

내용 없음.

Description

치환된 시클로프로필아미노-1,3,5-트리아진
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (15)

  1. 하기 일반식(I)의 화합물의 광학활성 이성질체 및 라세미 혼합물을 포함하여 치환된 시클로프로필아미노-1,3,5-트리아진 또는 이것의 비독성의 약학적으로 허용되는 산 부가염.
    상기 식에서, R1은 1 내지 3개의 탄소원자를 가지는 알킬 라디칼, 비치환 시클로알킬 라디칼 또는 최소한 하나의 알킬 라디칼로 치환된, 3 내지 5개의 탄소원자를 가지는 시클로알킬 라디칼을 나타내며, R2는 비스(2-히드록시에틸)아미노, 3-히드록시-1-아제티디닐, 3-메톡시-1-아제티디닐, 3-옥소-1-아제티디닐, 모르폴리노, 4-히드록시피페리디노, 티오모르폴리노, 티오모르폴리노 S-옥사이드, 티오모르폴리노 S,S-디옥시드, 3-티아졸리디닐, 3-티아졸리디닐 S-옥사이드, 3-티아졸리디닐 S,S-디옥시드 또는 8-옥사-아자비시클로[3,2,1]옥트-3-일 라디칼을 나타낸다.
  2. 제1항에 있어서, R2가 모르폴리노, 티오모르폴리노 또는 티오모르폴리노, S,S-디옥사이드 라디칼을 나타내는 치환된 시클로프로필아미노-1,3,5-트리아진 또는 이것의 비독성의 약학적으로 허용되는 산 부가염.
  3. 제1항에 있어서, 2-시클로프로필아미노-4-모르폴리노-6-n-프로필-1,3,5-트리아진 또는 이것의 비독성의 약학적으로 허용되는 산 부가염.
  4. 제1항에 있어서, 2-시클로프로필-4-시클로프로필아미노-6-모르폴리노-1,3,5-트리아진 또는 이것의 비독성의 약학적으로 허용되는 산 부가염.
  5. 제1항에 있어서, 2-시클로부틸-4-시클로프로필아미노-6-모르폴리노-1,3,5-트리아진 또는 이것의 비독성의 약학적으로 허용되는 산 부가염.
  6. 제1항에 있어서, 2-시클로부틸-4-시클로프로필아미노-6-티오모르폴리노-1,3,5-트리아진 또는 이것의 비독성의 약학적으로 허용되는 산 부가염.
  7. 제1항에 있어서, 2-시클로부틸-4-시클로프로필아미노-6-티오모르폴리노-1,3,5-트리아진 S,S-디옥사이드 또는 이것의 비독성의 약학적으로 하용되는 산 부가염.
  8. 하기식(II)의 클로로-시클로프로필아미노-1,3,5-트리아진을 식 R2H(III)아민과 반응시키는 것으로 이루어지는, 식(I)의 치환된 시클로프로필아미노-1,3,5-트리아진의 제조 방법.
    (상기 식에서, R1및 R2는 제1항에서 정의된 것과 같다.)
  9. 하기식(IV)의 클로로-1,3,5-트리아진을 식의 시클로프로필아민과 반응시키는 것으로 이루어지는, 식(I)의 치환된 시클로프로필아미노-1,3,5-트리아진의 제조 방법.
  10. 하기식(VI)의 N-시클로프로필비구아니드를 식 R1-COO Alk(VII)의 알킬에스테르와 반응시키는 것으로 이루어지는, 식(I)의 치환된 시클로프로필아미노-1,3,5-트리아진의 제조 방법.
    (상기 식에서, R1및 R2는 제1항에서 정의된 것과 같고, Alk는 1 내지 4탄소원자를 가지는 알킬 라디칼을 나타낸다.)
  11. 하기식(I)의 시클로프로필아미노-1,3,5-트리아진을 산화시키는 것으로 이루어지는, R2가 티오모르폴리노 S-옥사이드, 티오모르폴리노 S,S-디옥사이드, 3-티아졸리디닐 S-옥사이드 또는 3-티아졸리디닐 S,S-디옥사이드 라디칼을 나타내는, 식(I)의 치환된 시클로프로필아미노-1,3,5-트리아진의 제조 방법.
    (상기 식에서, R1은 제1항에서 정의된 것과 같고, R2는 티오모르폴리노 또는 3-티아졸리디닐 라디칼을 나타낸다.)
  12. 제1항에서 청구되는 시클로프로필아미노-1,3,5-트리아진의 치료적 유효량과 그것의 약학적으로 허용된 고체 또는 액체 희석제 또는 담체를 포함하는 약학 조성물.
  13. 알츠하이머병, 노인성 치매, 알츠하이머 타입과 관련되고 진화성인지 병리학과 관련된 장애를 가지는 환자의 치료방법으로서, 상기 환자에 제1항에 청구된 치환된 시클로프로필아미노-1,3,5-트리아진의 유효량을 투여하는 것으로 이루어지는 방법.
  14. 불안, 우울 및 기분장애 환자의 치료방법으로서, 상기 환자에 제1항에 청구된 치환된 시클로프로필아미노-1,3,5-트리아진의 유효량을 투여하는 것으로 이루어지는 방법.
  15. 염증현상 및 천식 환자의 치료방법으로서, 상기 환자에 제1항에 청구된 치환된 시클로프로필아미노-1,3,5-트리아진의 유효량을 투여하는 것으로 이루어지는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920013231A 1991-07-25 1992-07-24 치환된 시클로프로필아미노-1,3,5-트리아진 KR100221400B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919116039A GB9116039D0 (en) 1991-07-25 1991-07-25 Substituted cyclopropylamino-1,3,5-triazines
GB9116039.0 1991-07-25

Publications (2)

Publication Number Publication Date
KR930002327A true KR930002327A (ko) 1993-02-23
KR100221400B1 KR100221400B1 (ko) 1999-09-15

Family

ID=10698941

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920013231A KR100221400B1 (ko) 1991-07-25 1992-07-24 치환된 시클로프로필아미노-1,3,5-트리아진

Country Status (21)

Country Link
US (2) US5258513A (ko)
EP (1) EP0527117B1 (ko)
JP (1) JP3138540B2 (ko)
KR (1) KR100221400B1 (ko)
AT (1) ATE159719T1 (ko)
AU (1) AU648424B2 (ko)
CA (1) CA2072680A1 (ko)
DE (1) DE69222903T2 (ko)
DK (1) DK0527117T3 (ko)
ES (1) ES2109332T3 (ko)
FI (1) FI923314A (ko)
GB (1) GB9116039D0 (ko)
GR (1) GR3026017T3 (ko)
HU (1) HU218207B (ko)
IE (1) IE922422A1 (ko)
NO (1) NO300683B1 (ko)
NZ (1) NZ243681A (ko)
PL (2) PL169646B1 (ko)
RU (1) RU2095353C1 (ko)
UA (1) UA27749C2 (ko)
ZA (1) ZA924920B (ko)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025395A (en) * 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US5643960A (en) * 1994-04-15 1997-07-01 Duke University Method of delaying onset of alzheimer's disease symptoms
US5488056A (en) * 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
US6400819B1 (en) * 1996-03-28 2002-06-04 Hitachi, Ltd. Method and apparatus for executing communication in real-time and data structure for real-time data communication
WO1998011076A1 (de) * 1996-09-13 1998-03-19 Lonza Ag Verfahren zur herstellung von 6-methyl-2-methylamino-4-methoxy-1,3,5-triazin
US6538750B1 (en) 1998-05-22 2003-03-25 Cyberoptics Corporation Rotary sensor system with a single detector
US6292261B1 (en) 1998-05-22 2001-09-18 Cyberoptics Corporation Rotary sensor system with at least two detectors
FI105684B (fi) * 1998-08-21 2000-09-29 Neste Chemicals Oy Enantioselektiiviset kiraaliset sulfidikatalyytit, menetelmä niiden valmistamiseksi ja niiden käyttö stereoselektiivisiin epoksidointi-, syklopropanointi- ja atsiridinointireaktioihin
AU781849C (en) * 1999-06-17 2006-03-02 Synta Pharmaceuticals Corp. Inhibitors of IL-12 production
US6384032B1 (en) * 1999-06-17 2002-05-07 Shionogi Bioresearch Corp. Inhibitors of IL-12 production
MXPA02001830A (es) 1999-08-21 2002-08-12 Byk Gulden Lomberg Chem Fab Combinacion sinergica de inhibidores de pde y agonista de beta 2 adrenoceptor.
CN1098876C (zh) * 1999-09-21 2003-01-15 上海赛璐化工股份有限公司 一种长碳链共聚酰胺及其制备方法
US6943161B2 (en) * 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
US6680315B2 (en) * 2000-06-15 2004-01-20 Synta Pharmaceuticals Corp. Triazine compounds
US7323462B2 (en) * 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EA200501548A1 (ru) 2003-04-01 2006-02-24 Апплайд Резеч Системз Арс Холдинг Н.В. Ингибиторы фосфодиэстераз при бесплодии
TWI359017B (en) * 2003-11-10 2012-03-01 Synta Pharmaceuticals Corp Heteroaryl-hydrazone compounds
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
DK2170930T3 (da) 2007-06-04 2012-11-05 Synergy Pharmaceuticals Inc Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
ES2664873T3 (es) 2011-03-01 2018-04-23 Synergy Pharmaceuticals Inc. Proceso de preparación de agonistas de guanilato ciclasa C
WO2013022279A2 (en) * 2011-08-08 2013-02-14 Hanall Biopharma Co., Ltd. N1-cyclic amine-n5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same
EP2958577A2 (en) 2013-02-25 2015-12-30 Synergy Pharmaceuticals Inc. Guanylate cyclase receptor agonists for use in colonic cleansing
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
KR20220147691A (ko) 2013-08-09 2022-11-03 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160831A (en) * 1976-08-19 1979-07-10 Ciba-Geigy Corporation Novel insecticides
DE2963654D1 (en) * 1978-02-03 1982-11-04 Ciba Geigy Ag 2-methylthio-4-cyclopropylamino-6-(alpha,beta-dimethylpropylamino)-s-triazine and the use of triazine derivatives as seewater algicides
GB8819493D0 (en) * 1988-08-16 1988-09-21 Ucb Sa 2-amino-4-morpholino-6-propyl-1 3 5-triazines
GB8819494D0 (en) * 1988-08-16 1988-09-21 Ucb Sa Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments

Also Published As

Publication number Publication date
ZA924920B (en) 1993-04-28
DE69222903D1 (de) 1997-12-04
PL169247B1 (pl) 1996-06-28
HU9202441D0 (en) 1992-10-28
NO922922L (no) 1993-01-26
RU2095353C1 (ru) 1997-11-10
JP3138540B2 (ja) 2001-02-26
ES2109332T3 (es) 1998-01-16
AU2053492A (en) 1993-01-28
HUT66218A (en) 1994-10-28
FI923314A0 (fi) 1992-07-21
HU218207B (hu) 2000-06-28
ATE159719T1 (de) 1997-11-15
UA27749C2 (uk) 2000-10-16
DE69222903T2 (de) 1998-03-26
IE922422A1 (en) 1993-01-27
NO922922D0 (no) 1992-07-23
US5258513A (en) 1993-11-02
DK0527117T3 (da) 1998-05-18
NZ243681A (en) 1997-06-24
EP0527117A1 (fr) 1993-02-10
AU648424B2 (en) 1994-04-21
CA2072680A1 (en) 1993-01-26
KR100221400B1 (ko) 1999-09-15
GR3026017T3 (en) 1998-04-30
US5348956A (en) 1994-09-20
GB9116039D0 (en) 1991-09-11
FI923314A (fi) 1993-01-26
EP0527117B1 (fr) 1997-10-29
NO300683B1 (no) 1997-07-07
JPH06220026A (ja) 1994-08-09
PL295403A1 (ko) 1993-02-08
PL169646B1 (pl) 1996-08-30

Similar Documents

Publication Publication Date Title
KR930002327A (ko) 치환된 시클로프로필아미노-1, 3, 5-트리아진
HUT61742A (en) Process for producing cyclic amide derivatives and pharmaceutical compositions comprising same
ZA932168B (en) Naphthylalkylamines, process for preparing them and pharmaceutical compositions containing them
ATE143943T1 (de) Arylglycinamidderivate, verfahren zur deren herstellung und deren verwendung zur therapie der dysurie
GR3030798T3 (en) 2-(Piperidin-4-yl, pyridin-4-yl and tetrahydropyridin-4-yl)benzofuran-7-ol and carbamate derivatives, their preparation and their use as acetylcholinesterase inhibitors.
FI903819A0 (fi) 1,3-dihydro-1-(pyridinylamino)-2h-indol- 2-oner, foerfarande foer framstaellning av dem och anvaendning av dem som laekemedel.
NZ226415A (en) Spiro-oxathiolane/quinuclidine derivatives and pharmaceutical compositions
HUT54156A (en) Process for producing new n-heteroarylpurine-6-amine derivatives and pharmaceutical compositions comprising such compounds
HU908014D0 (en) Process for producing amino-carbonyl-carbamates analogues to physostigmine and pharmaceutical preparatives containing these compounds
DE69500274T2 (de) Thiazin- oder Thiomorpholinderivate
DK0573318T3 (da) 4-phenylcarbamoyl-3-isoxazolcarboxylsyreforbindelser, fremgangsmåde til deres fremstilling, farmaceutiske præparater med in
FI103887B (fi) Menetelmä terapeuttisesti käyttökelpoisten imidatsolyylimetyyli-pyridiinien valmistamiseksi
HUT61755A (en) Process for producing 3-(1,2-benzisoxazol-3-yl)-4-pyridineamines and their derivatives
ATE123776T1 (de) Aminoalkylchromone, verfahren zu ihrer herstellung und diese enthaltende zusammensetzungen.
DE69112785D1 (de) Phthalidylidenderivate von Carnitin und Alkanoylcarnitinen sowie diese enthaltende pharmazeutische Mittel.
GR3021200T3 (en) (Cyclohexyl)-alken compounds, process for their preparation and pharmaceutical compositions containing them.
DE69025274D1 (de) Hexahydro-1H-chino[4,3,2-ef][1,4]benzoxazepine und verwandte Verbindungen und Zwischenprodukte zur Herstellung und Verwendung als Arzneimittel
GR3019469T3 (en) 2-(3-Phenylpropyl)hydrazines, intermediates in and a process for the preparation thereof, and their use as medicaments
HU912675D0 (en) Process for producing derivatives of carbamoil-1-(pyridinyl-alkyl)-1h-indole and -indole

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee